Skip to main content

Table 2 Mean and ± SEM sample data for the two centre cohorts used for the biomarker discovery and validation cohorts

From: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

Biomarker discovery cohort Control n = 15 LBD n = 10   
Gender (M:F) 5:10 6:4   
Mean Age at Sampling (yrs ± SD) 61 ± 9.9 71.9 ± 4.3   
Median disease duration (yrs ± SD) n/a 3.4 ± 1.57   
Mean Aβ42 levels (pg/ml ± SD) 905.41 ± 237 695.6 ± 330.7   
Mean h-tau levels (pg/ml ± SD) 136.58 ± 162 523 ± 432   
Mean p-tau181 levels (pg/ml ± SD) 19.33 ± 11.11 52 ± 39   
Validation cohort Control n = 15 LBD n = 17 PD n = 7 AD n = 16
Gender (M:F) 5:10 10:7 5:2 6:10
Mean Age at Sampling (yrs ± SD) 61 ± 9.9 72.1 ± 5.5 68.1 ± 3.4 78.1 ± 6.67
Median disease duration (yrs ± SD)   3.3 ± 1.9 4.1 ± 2.78  
Mean Aβ42 levels (pg/ml ± SD) 905.41 ± 237 663.5 ± 268 886.4 ± 232 503.68 ± 165.88
Mean h-tau levels (pg/ml ± SD) 136.58 ± 162 679 ± 673 139 ± 93 733.77 ± 481.25
Mean p-tau levels (pg/ml ± SD) 19.33 ± 11.11 64.5 ± 48.8 26 ± 11 93.38 ± 31.55
  1. Control, LBD, PD and 7 AD samples were received from centre 1 and 9 AD samples from centre 2. As the two centres share the same clinical workup for AD the data in Table 2 has been combined